About Quadrant Biosciences
Quadrant Biosciences is a company based in Syracuse (United States) founded in 2015. Quadrant Biosciences has raised $14.01 million across 9 funding rounds from investors including NIH and HHS. Quadrant Biosciences operates in a competitive market with competitors including Sunbird Bio, BrainSpec, Courtagen, Mursla and Imeka, among others.
- Headquarter Syracuse, United States
- SectorsHealthcare
- Email••••••••
- Website quadrantbiosciences.com
- Social LinkedIn Facebook
- Total Equity Funding$14.01M (USD)
in 9 rounds
- Latest Funding Round$3.5M (USD), Series B
Aug 2023
- InvestorsNIH
& 1 more
Funding Insights of Quadrant Biosciences
Quadrant Biosciences has successfully raised a total of $14.01M across 9 strategic funding rounds. The most recent funding activity was a Series B round of $3.5 million completed in August 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $14.01M
- Total Rounds 9
- Last Round Series B — $3.5M
- First Round $3.6M
(Apr 2016)
- Investors Count 2
All 9 funding rounds of Quadrant Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
2 investors in total: 2 institutional.
Investors in Quadrant Biosciences
Quadrant Biosciences has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include NIH and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States |
Investor details for Quadrant Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Quadrant Biosciences
9 people are tracked at Quadrant Biosciences (4 in leadership, 3 in board & advisors, 2 in team).
| Name | Role | Group |
|---|---|---|
Karen Canestrare | VP Finance And Treasurer | Leadership |
Mary Katherine Buckley | Director Of Accounting | Leadership |
Charles Marra | VP Of Technology | Leadership |
Eric B. | Director Of Technical Project Management | Leadership |
Andrew Rock | Director | Board & advisors |
James Croke | Director | Board & advisors |
Peter Cohen | Director | Board & advisors |
Julie Vomund | Legal Department Manager | Team |
Chris Horacek | Deputy General Counsel | Team |
Complete people profiles for Quadrant Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Quadrant Biosciences
3 dated milestones of Quadrant Biosciences across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Quadrant Biosciences is founded.
- Funding First funding round of $3.6M.
- Funding Latest funding round, Series B, of $3.5M.
Competitors of Quadrant Biosciences
Quadrant Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sunbird Bio, BrainSpec, Courtagen, Mursla and Imeka, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sunbirdbio.com | 2020 | Singapore | $14M | – | Diagnostic technologies for infectious, cancer, and neurological diseases are developed. | |
| brainspecmed.com | 2015 | Boston, United States | $5.59M | – | Web-based MRS platform for brain metabolite analysis is utilized. | |
| courtagen.com | 2009 | Woburn, United States | $41.31M | 128 | Provides solutions for neurological and metabolic disorders. | |
| mursla.com | 2017 | London, United Kingdom | $547,194 | 9 | Diagnostic devices for cancer detection are developed using nanostructures. | |
| imeka.ca | 2011 | Sherbrooke, Canada | – | 19 | MRI-based diagnostic software using AI and diffusion imaging is developed. | |
| syntheticmr.com | 2007 | Linkoping, Sweden | – | – | Software solutions for Magnetic Resonance Imaging are provided. | |
| neurovigil.com | 2007 | Mountain View, United States | $250,000 | – | Solution provider for analysis of brain data in medical applications |
Detailed competitors of Quadrant Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Quadrant Biosciences
Complete news archive for Quadrant Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Quadrant Biosciences
10 companies that operate in the same segment as Quadrant Biosciences (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Quadrant Biosciences
Quadrant Biosciences was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Quadrant Biosciences is headquartered in Syracuse, United States. It is registered at Syracuse, New York, United States.
Quadrant Biosciences is a funded company, having raised a total of $14.01M across 9 funding rounds to date. The company's 1st funding round was a Series A of $3.6M, raised on Apr 2016.
Quadrant Biosciences develops diagnostic products for brain health, creating evolutionary advancements in concussive assessment and autism detection. The company is developing multiple products with different modalities that address ASD and brain concussion. Their brain function tests comprise of a set of tools for the functional assessment of brain health called ClearEdge Brain Health Toolkit and an Autism screening test. The company is also developing a test for the objective detection of concussion by measuring a set of miRNA markers in the patients saliva.
Quadrant Biosciences's top competitors include Sunbird Bio, Mursla and SyntheticMR.